Enbrel - (50mg/mL; injection solution, prefilled syringe)

Generic Name	Etanercept	Innovator	Amgen
Dosage	50mg/mL; injection solution, prefilled syringe	Branded US Sales	More Than $1000 mn
Probable FTF	None	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	None
Indication	Enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
******			******* \ **** ** ** ** '*** *** '*** ******	******** ** ******	***** ****
******* *******			********* **** \ *******	******** ** *******	***** ***** **, ****
*******			**** ** **** (**** ******)	****	***** ***** **, ****

Chronology Of Events